SecBot SecBot
SECBOTREPLAY Home › Report › APLS

APLS · Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common…

Apellis Pharmaceuticals, Inc. · 25-NSE filed May 14, 2026 at 09:52 ET

At the news

NEUTRALIMPACT 2/10

25-NSE filed May 14, 2026 at 09:52 ET

Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May 14, 2026, following the completion of Biogen's acquisition. The delisting is a procedural step after the merger closed, with APLS stockholders receiving $41.00 per share plus CVRs.

  • Form 25-NSE filed by Nasdaq Stock Market LLC to delist Apellis common stock under Rule 12d2-2(a)(3).
  • Effectiveness date is May 14, 2026, the same day as the filing.
  • Delisting follows Biogen's completed acquisition of Apellis for $41.00 per share plus CVRs.
  • The security is removed from listing and registration due to the merger, not due to any operational failure.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access